Walgreens Boots Alliance is partnering with primary care provider VillageMD to open doctor offices attached to the pharmacy chain’s drugstores across the United States.
Biogen announced the widely awaited submission of a U.S. marketing application for the experimental Alzheimer’s therapy aducanumab, sending the company’s shares up more than 8 percent before the bell.
GlaxoSmithKline is providing pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.
With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate NVX‑CoV2373.
Regeneron Pharmaceuticals received a $450 million contract to manufacture and supply a two-antibody cocktail for the treatment and prevention of COVID-19 as part of Operation Warp Speed from the Biomedical Advanced Research and Development Authority (BARDA).
Britain’s GSK said an injection of the company’s cabotegravir drug given every two months was found to be 65 percent more effective in preventing HIV infections than Gilead’s Truvada daily oral pills.
The U.S. Environmental Protection Agency (EPA) approved use of UK-based Reckitt Benckiser’s Lysol Disinfectant Spray against COVID-19.
Companies Face Challenge of Enrolling Patients in COVID-19 Vaccine Studies
Business, Clinical Data, Clinical Trials, Coronavirus Disease 2019 (COVID-19), COVID-19 Vaccines, Manufacturing, Messenger RNA (mRNA) Vaccines, Oxford University, Patient Enrollment, R&D, The Wall Street Journal, World Health OrganizationCompanies Face Challenge of Enrolling Patients in COVID-19 Vaccine Studies Published: July 6, 2020 By Mark Terry BioSpace As of June 29, there were 13 vaccines against COVID-19 in […]
ObsEva announced topline data from the PRIMROSE 1 and 2 Phase III trials of Yselty (linzagolix) for uterine fibroids.
Emergent and J&J Ink COVID-19 Vaccine Deal
Adenovirus, Business, Clinical Data, Clinical Trials, Contract Development and Manufacturing (CDMO), Contract Development Manufacturing Organization (CDMO), COVID-19 Vaccines, Department of Health and Human Services (HHS), Manufacturing, National Institute of Allergy and Infectious Diseases (NIAID), R&D, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Emergent BioSolutions entered a five-year manufacturing services deal with Janssen Pharmaceutical to manufacture Johnson & Johnson’s Ad26.COV2-S COVID-19 vaccine.